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OBJECTIVES We sought to detect cross-talk between the beating heart and coronary vascular bed during
myocardial ischemia and to test the hypothesis that the cross-talk is mediated by pertussis
toxin (PTX)-sensitive G proteins (GPTX) in vessels.
BACKGROUND Coronary flow is closely related to the myocardial metabolic state, indicating the existence of
a close interaction between cardiac muscle and coronary vascular beds. Experimental methods
for the analysis of the interaction, however, have not been established.
METHODS Coronary detector vessels (DVs) were isolated from rabbit hearts. One end of the vessel was
cannulated to a micropipette, and the other end was ligated. After the DV was pressurized
(60 cm H2O), it was gently placed on the myocardium, which was perfused by the left
anterior descending coronary artery (LAD) of anesthetized, open-chest dogs (n  23). The
LAD was occluded, and the DV diameter was observed using an intravital microscope with
a floating objective system. To evaluate the involvement of GPTX, the DV was pre-incubated
with PTX (100 ng/ml).
RESULTS The LAD occlusion of the beating heart produced significant dilation of DVs (241 25 m)
by 10%. The DVs pretreated with PTX (250  27 m) did not dilate in response to
myocardial ischemia. N-nitro-L-arginine (100 mol/l), but not glibenclamide (5 mol/l),
abolished the ischemia-induced DV dilation.
CONCLUSIONS We have established experimental methods for direct analysis of the interaction between the
myocardium and coronary microvessels. We conclude that the ischemic myocardium releases
transferable vasodilator signals that are transduced by means of the GPTX located in the
vascular walls. The nitric oxide pathway is involved in the signal transduction. (J Am Coll
Cardiol 2002;39:1859–65) © 2002 by the American College of Cardiology Foundation
Because the cardiac metabolic rate is high due to its
continuous beating, the changes in oxygen uptake are
mainly determined by coronary flow changes. In fact,
previous studies have shown a close correlation between
coronary flow and the metabolic state of the heart (1,2).
However, because of the lack of adequate methods for
evaluating the cross-talk between cardiac muscle and the
coronary vascular bed, it has not been well clarified how
vasomotor signals from cardiac muscle cells modulate the
tone of coronary vessels.
To identify the mechanisms of the regulation of coronary
microvascular tone, many studies have been performed. We
previously observed the coronary microvascular responses
during autoregulation, brief ischemia and metabolic stimu-
lation in vivo (3–5) and demonstrated the importance of
adenosine triphosphate-sensitive potassium channels
(KATP) and pertussis toxin (PTX)-sensitive G proteins
(GPTX) in the regulatory mechanism. However, vascular
responses of the beating heart are determined by many
factors, such as myogenic control, shear stress-induced
dilation, metabolic factors and neurohormonal control (6,7).
For example, under an ischemic condition, the vascular tone
is affected not only by myocardial metabolic changes but
also by decreases in the intraluminal distending pressure,
decreases in shear stress, neurohormonal control and so
forth. Therefore, it is difficult to precisely evaluate the
vasodilator signals from the myocardium in vivo.
On the other hand, in vitro studies have been performed
to investigate the effects of vasoactive factors that could be
involved in metabolic vascular control. Adenosine (8) and a
decrease in pH (9), which have been suggested to be
involved in coronary flow regulation during hypoxia, isch-
emia and increased metabolic demand of the heart, have
been examined in isolated coronary vessels. However, it is
difficult to extrapolate the relevance of these vasoactive
factors in the metabolic control of the vascular diameter in
vivo from the in vitro studies. To investigate the cross-talk
between coronary vessels and the myocardium, we have
developed a new experimental method in which isolated
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detector vessels (DVs) were placed on the beating heart.
With this method, the distending pressure of the DVs, the
neurohormonal environment around the isolated vessels and
the metabolic state of the beating heart can be indepen-
dently controlled.
Heterotrimeric G proteins are crucial in the transduction
of various biologic signals from the outside to the inside of
the cell (10–12). We have shown that they are important
regulatory modulators in the coronary circulation because
they play a pivotal role in the control of the coronary
microvascular tone in vivo (4,5). Therefore, we investigated
whether the signals released from myocytes under the
condition of ischemia are sensitive to PTX.
We have established a new method by which we can
separately control the beating heart and coronary vasculature
by combining isolated vessels with a beating-heart prepara-
tion. Our objectives were to clarify whether the ischemic
myocardium releases transferable vasodilator signals and
whether the vasodilator signals from the ischemic heart are
transduced by means of the GPTX located in the vascular
wall. We also investigated the involvement of KATP and
L-arginine–nitric oxide (NO) pathway in the signal trans-
duction.
METHODS
Preparation of DVs. Male Japanese white rabbits (n  23,
weight 2.4  0.1 kg, 10 to 13 weeks old) were anesthetized
with an intravenous injection of pentobarbital (50 mg/kg)
and heparinized (800 U intravenously) to prevent blood
coagulation. After the rabbits were sacrificed by bleeding
from the carotid artery, the hearts were quickly excised and
immediately immersed in chilled physiologic saline solution
(in mmol/l: NaCl 145.0, KCl 4.7, CaCl2 2.0, MgSO4 1.17,
NaH2PO4 1.2, pyruvate 2.0, calcium disodium EDTA 0.02,
3-[N-morpholino]-propanesulfonic acid 3.0 and glucose
5.0), maintained at 0°C and buffered to pH 7.40. A coronary
arterial vessel perfusing the left ventricle (LV) (100 to 400 m)
was carefully and gently dissected without excessive force.
One end of the vessel was cannulated to a polyethylene
micropipette (filled with filtered PSS), the tip of which was
tapered (100 m), and tied with a monofilament of silk
suture thread (diameter 2 m). The polyethylene micropi-
pette was connected to a pressure reservoir. The other end
of the vessel was ligated completely, and the intraluminal
pressure was monitored with a strain-gauge transducer
(TC0406S01, Baxter Corp.) to detect vascular leaks. Vessels
with any leakage were not used for further experiments. The
DV was incubated in oxygenated warm PSS (38°C) until
use.
Beating-heart preparation. Mongrel dogs of either gender
(n 23, body weight 2.5 to 12.4 kg [mean 7.5 0.5]) were
used and prepared as described in our previous in vivo
studies (13,14). Briefly, the dogs were anesthetized with
alpha-chloralose (60 mg/kg, Wako Chemicals, Osaka, Ja-
pan) and artificially ventilated. The right jugular vein was
cannulated for administration of the anesthetic agents and
fluid infusion. A catheter was introduced into the right
carotid artery, and its tip was placed in the ascending aorta
for the measurement of aortic pressure with a strain-gauge
transducer (TC0406S01, Baxter Corp.). A thoracotomy was
performed, and the pericardium was cut to expose the heart
surface. The electrocardiogram was monitored throughout
the experiment.
The heart rate was kept constant at 100 to 110 beats/min
by left atrial pacing after suppression of the sinus node with
an injection of formaldehyde (0.5 ml). Two 24-gauge,
stainless-steel needles were inserted horizontally (5 to 7 mm
apart) into the mid-myocardium of the LV. Both ends of
each needle were fixed to a needle holder held with coil
springs. This apparatus limits the excessive perpendicular
and horizontal movement of the heart, thereby keeping the
region of interest within the observation field.
The main trunk of the left anterior descending coronary
artery (LAD) was dissected, and a snare (4-0 silk suture
thread) was placed around the LAD for coronary occlusion.
In several experiments, a small branch of the LAD distal to
the occlusion point was cannulated with a small catheter
(outer diameter 0.67 mm), and the distal coronary pressure
was measured.
The investigation conformed to the “Guide for the Care
and Use of Laboratory Animals,” published by the U.S.
National Institutes of Health (NIH Publication No. 85-23,
revised 1996), and the experimental protocols were ap-
proved by the institutional Committee for Animal Experi-
ments.
Bioassay method. The incubated DV was gently placed on
the LAD perfusion area of the beating LV of the dog. Only
one DV was used for each experiment. The DV and the
heart surface were kept moist throughout the experiment by
continuous superfusion of PSS at a rate of 60 ml/h. The
entire superfusion line was continuously warmed by a warm
circuit, using a thermostat to keep the superfusate temper-
ature at 37°C on the heart surface. An internal pressure of
60 cm H2O was applied to the vessels to produce intrinsic
tone, and the internal diameter was observed.
Image acquisition system. For visualization of the DV
placed on the beating LVs, an intravital microscope system
equipped with a floating objective was used. This optical
Abbreviations and Acronyms
DV  detector vessel
GPTX  pertussis toxin-sensitive G proteins
KATP  adenosine triphosphate-sensitive potassium
channels
LAD  left anterior descending coronary artery
L-NNA  N-nitro-L-arginine
LV  left ventricle
NO  nitric oxide
PSS  physiologic saline solution
PTX  pertussis toxin
SNP  sodium nitroprusside
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system was originally developed for visualization of coronary
microvessels of the beating-heart surface in vivo in our
laboratory (13,14). With this system, it is possible to
continuously observe the surface of the beating heart. The
microscope objective was a Leitz model PL-fl (10; nu-
meric aperture of 0.30). An objective lifter was used to
carefully adjust the distance between the objective and
vessels, so as not to compress the DV.
Epi-illumination by a stroboscopic light source was ap-
plied to obtain the image of the DV and measure the
internal diameters. A polarizing filter (IGS, Nikon, Tokyo,
Japan) was used to minimize reflected light from the surface
of the heart. Obtained images were monitored and recorded
at 200 frames/s, using a high-speed video camera (model
MHS-200, Nac Inc., Tokyo, Japan) with an image inten-
sifier (C 3100, Hamamatsu Photonics, Hamamatsu, Japan).
The spatial resolution of this system was 2 m.
Vascular diameter measurement. The inner diameters of
the DVs were measured on a high-resolution monitor
screen (C 1846-01, Hamamatsu Photonics) using a video
manipulator (C 2117, Hamamatsu Photonics). On the
monitor screen, one cursor was set on the vessel wall of
interest, and another cursor was set on the nearest point of
the other side of the vessel wall. The distance between the
two cursors was automatically calculated by the video
manipulator, thereby yielding the vascular diameters. Vas-
cular diameters were measured at least three times during
the end-diastolic phase. To evaluate the diameter changes
for each intervention, the diameters were measured at the
same point using the polyethylene micropipette or the tying
thread as a reference point.
Experimental protocols. Experiments were performed ap-
proximately 1 h after placing the DVs onto the beating
hearts, when all monitored variables had become stable and
the intrinsic tone of the DVs had developed.
PROTOCOL 1 (N  10). We investigated whether the ischemic
myocardium releases vasoactive signals that are transmitted
to DVs. After measurement of the monitored baseline
variables, the LAD of the beating heart was completely
occluded. Images of the DV were collected at 2, 3, 5 and
10 min after the onset of ischemia. Hemodynamic variables
were collected 5 and 10 min after the onset of ischemia.
PROTOCOL 2 (N  4). We investigated whether the vasoac-
tive signals from the ischemic myocardium are transmitted
to DVs by GPTX located in the vascular wall. For this
purpose, the DVs were pretreated with PTX (100 ng/ml)
for 2 h. Thereafter, the DV was placed on the beating
hearts. After measuring the baseline data, the LAD of the
beating heart was completely occluded. Vascular images and
hemodynamic data were collected in the same fashion as in
Protocol 1.
In additional experiments, we tested whether the cross-
talk between the ischemic myocardium and the DV involves
the NO pathway or KATP activation, or both, because we
have previously shown that microvascular GPTX is function-
ally linked with those mechanisms (15). For these purposes,
we used N-nitro-L-arginine (L-NNA; 100 mol/l; n  4)
to block the NO pathway, and glibenclamide (5 mol/l;
n  5) to block KATP. Because these agents are reversible
blockers, we superfused them onto the DV after placing it
on the myocardium throughout the experiment, unlike PTX
experiments. Twenty minutes after the onset of superfusion
of these blockers, the LAD was occluded, and the DVs were
observed in the same manner as in Protocols 1 and 2. The
images of the DVs were obtained 5 min after the ischemia.
In each experiment, ischemia of the myocardium on
which the DV was placed was confirmed by the dyskinetic
wall motion and cyanotic color changes of the heart. At
the end of the experiment, sodium nitroprusside (SNP;
100 mol/l) was superfused for 5 min to produce maximal
dilation.
Drugs. The PTX solution (200 g/ml, Seikagaku Co.,
Tokyo, Japan) was freshly diluted with PSS to 100 ng/ml on
each experimental day. Glibenclamide (Sigma, St. Louis,
Missouri) was dissolved with dimethylsulfoxide at first, and
then the target concentration was obtained with PSS. The
final concentration of dimethylsulfoxide was 0.005 vol%.
L-NNA (Sigma) and SNP (Wako Chemicals) were freshly
dissolved in PSS to the desired concentrations.
Data analysis. The aortic pressure (phasic and mean) and
distal coronary pressure (mean) were recorded on a Recti-
graph (model 8K, San-Ei Sokki, Tokyo, Japan). All vari-
ables were expressed as the mean value  SEM. The
responses of the DV diameters to myocardial ischemia were
expressed as the percent change in diameter. When the
baseline diameter was 90% of the maximal diameter
produced by SNP, the vessel was discarded (n  23). When
ventricular fibrillation occurred during the protocol, the
experiment was excluded from the data analysis (n  7).
Changes in aortic pressure and vascular diameters were
statistically analyzed by using one-way analysis of variance
for repeated measures and the Student t test for paired
samples, with the Bonferroni correction applied to detect
the time point when significant changes occurred. At p 
0.05, the differences were accepted as significant.
RESULTS
The aortic pressure slightly decreased at 5 min, but not at 10
min, in Protocols 1 and 2 (Table 1). The blood gas and pH
were kept within physiologic ranges before ischemia (Table
1). In five cases (3 in Protocol 1, 2 in Protocol 2), we
measured the distal coronary pressure of the occlusion site
and found that the coronary occlusion produced a signifi-
cant reduction in the perfusion pressure in both Protocol 1
(before ischemia: 91  12 mm Hg; 5-min ischemia: 23 
3 mm Hg; 10-min ischemia: 24  4 mm Hg) and Protocol
2 (before ischemia: 108  10 mm Hg; 5-min ischemia: 31
 1 mm Hg; 10-min ischemia: 33  3 mm Hg).
After incubation in a bath of PSS, the DVs were placed
on the beating heart. The focusing point for the heart’s
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surface was lower than that for the DVs, so that the DVs
were not compressed by the floating objective system.
Figure 1 shows the responses of the DVs in Protocol 1.
The DVs (10 vessels; baseline diameter: 241  25 m)
began to dilate significantly 2 min after the induction of
ischemia. The dilation attained its peak at 3 min and
continued for 10 min.
In contrast, in Protocol 2, the DVs pretreated with PTX
(4 vessels; baseline diameter: 250  27 m) did not dilate
in response to myocardial ischemia (Fig. 2). There were no
differences in the dilator responses to SNP (100 mol/l)
between Protocol 1 and Protocol 2 (Fig. 3). Because only
DVs were pretreated with PTX, these results indicate that
the vasodilator signals from the ischemic myocardium are
transduced to the DVs by GPTX, which is located in the
vascular wall.
When L-NNA (100 mol/l) was superfused onto the
bioassay system (n  4; baseline diameter: 208  26 m),
the DV did not dilate but actually constricted in response to
myocardial ischemia (18.5  7.4% at 5 min after LAD
occlusion; p  0.05 vs. Protocol 1). Sodium nitroprusside
dilated the DVs by 13.5  4.5%.
When glibenclamide (5 mol/l) was superfused onto the
bioassay system (n  5; baseline diameter: 194  24 m),
the DVs still dilated in response to myocardial ischemia
(6.5  3.8%; p  NS vs. Protocol 1). Sodium nitroprusside
dilated the DVs by 17.9  1.8%.
DISCUSSION
In the present study, we have established a new experimen-
tal method for analyzing the interaction between cardiac
muscle and coronary arterial vessels. With this method, we
have found the following: 1) the ischemic heart releases
vasoactive signals that cause vascular dilation. The vessels
begin to dilate within 2 min, and the maximal dilation
continues for 10 min. 2) The vasodilator signals from the
ischemic heart are transduced by GPTX, which is located in
the vascular wall. 3) Production of NO is involved in this
signal transduction.
Methodologic consideration. This is a unique method
combining isolated vessels with a beating-heart preparation
for analyzing the interaction between the heart and the
Table 1. Aortic Pressure, Blood pH and Blood Gas Data of
Dogs in Protocols 1 and 2
Mean Aortic
Pressure
(mm Hg) Blood pH
PO2
(mm Hg)
PCO2
(mm Hg)
Protocol 1 (n  10)
Before ischemia 103  8 7.40  0.01 99  7 32  2
5-min ischemia 94  7*
10-min ischemia 98  7
Protocol 2 (n  4)
Before ischemia 113  7 7.43  0.04 107  19 31  2
5-min ischemia 104  8
10-min ischemia 107  6
*p  0.05 compared with before ischemia. Data are presented as the mean value  SD.
PO2  partial pressure of oxygen; PCO2  partial pressure of carbon dioxide.
Figure 1. The detector vessel responses during myocardial ischemia in
Protocol 1. Significant dilation was observed at 2, 3, 5 and 10 min after the
induction of ischemia. *p  0.05 compared with baseline.
Figure 2. The detector vessel (DV) responses during myocardial ischemia
in Protocol 2. In contrast to Protocol 1, no significant dilation was observed
during ischemia, when the DVs were pretreated with pertussis toxin (100
g/ml).
Figure 3. Column graphs showing the detector vessel responses to super-
fusion of sodium nitroprusside (SNP) (100 mol/l). In both groups, the
vessels were significantly dilated. There was no difference in the magnitude
of SNP-induced dilation between Protocols 1 and 2.
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coronary vasculature. The detector coronary vessels were
placed directly on the beating heart, and time-matching,
time-dependent observation of the DVs could be per-
formed. We believe that the dilation of the DVs caused by
myocardial ischemia was not an artifact, because the dilation
was specifically blocked by PTX, and the dilator capacity of
the DVs for SNP was well preserved.
In the present bioassay method, the beating heart and the
DV could be controlled independently of each other. In
these experiments, the intravascular distending pressure was
set at 60 cm H2O throughout the experiment. In the in vivo
observations of the coronary circulation, coronary occlusion
produced a decrease in the intravascular pressure along with
the myocardial ischemic condition, both of which affect the
vascular tone. The vasorelaxation of vessels 200 m
during ischemia cannot be detected in an in vivo prepara-
tion, possibly because the vasorelaxation is balanced by
vascular collapse caused by the decrease in intravascular
pressure (3). The present method is superior in terms of its
precise detection of vasodilator signals from the ischemic
myocardium. Furthermore, pharmacologic intervention can
also be separately applied to the myocardium and DVs. We
applied PTX only to the DVs in the present experiment.
Another advantage of the present method is the minimi-
zation of neurohormonal effects. Because the DVs are not
innervated and the effect of the beating heart’s hormonal
changes on the DV would be minimal, we can precisely
assess the dilatory metabolic signal released from the beating
heart.
With this method, we could detect, with sensitivity, the
dilator signals from the ischemic myocardium, as the dila-
tion occurred as quickly as 2 min after the induction of
myocardial ischemia. Our previous study, however, has
shown that microvascular dilation takes place 30 s after the
onset of coronary occlusion (16). The time lag of 1.5 min
may have been caused by the barrier function of the
epicardium between the surface of the heart and the DV.
There is an earlier study that focuses on the interaction
between cardiomyocytes and coronary microvessels. Tiefen-
bacher et al. (17) attempted to evaluate vasoactive signals
from myocytes to reconcile the paradox that alpha-
adrenergic activation in vivo causes constriction of coronary
arterioles, whereas an alpha-agonist does not constrict
isolated arterioles. For this purpose, they put a supernatant
of enzymatically resolved myocytes onto the isolated coro-
nary vessels and demonstrated that some vasoconstrictive
factors are released from myocytes upon alpha-stimulation.
Compared with the method by Tiefenbacher et al., the
present method is more physiologic because the signals we
evaluated were derived from beating hearts, not isolated
myocytes. Therefore, interaction between the myocardium
and coronary vessels that takes place during physiologic and
pathophysiologic phenomena, such as ischemia, can be
investigated. It is also possible to follow the time course of
the interaction by using the present method.
Relatively large microvessels (250 m) were used for
DVs. The smaller the microvascular size, the larger the
amount of vascular resistance these microvessels bear. How-
ever, smaller microvessels have thinner vascular walls, which
are harder to detect on the beating heart. As a previous
study has shown that microvessels 200 m bear 25% of
the total coronary resistance (18), we believe that the present
findings are still relevant to the regulation of coronary
resistance.
PTX-sensitive mechanisms during ischemia. In a previ-
ous study, we showed that vasodilation caused by a reduc-
tion in perfusion pressure in the in vivo condition was totally
abolished by PTX application (4), indicating the importance
of GPTX in the signal transduction for microvascular dila-
tion in response to low perfusion. These findings are
consistent with the present data. That study, however, did
not answer the question of whether hypoperfusion-induced
vasomotion is mediated by GPTX located in the microvas-
cular wall or in the myocardium, because PTX was super-
fused onto the heart surface, leading to blockade of GPTX
both in coronary microvessels and the myocardium around
them. GPTX is known to exist not only in vessels but also in
the myocardium (19,20). In contrast, in the present study,
because only vessels were pretreated with PTX, which
irreversibly blocks GPTX, we can now conclude that vaso-
motor signals from the ischemic myocardium activate GPTX
located in the vascular wall.
To identify the mechanisms distal to GPTX activation, we
investigated the effect of blockade of the NO pathway and
KATP on the microvascular dilation induced by myocardial
ischemia, because we have previously shown that GPTX is
functionally linked with those two downstream mechanisms
in coronary microvessels (15).
L-NNA completely abolished the dilation of the DVs,
whereas glibenclamide was without effect. These results
indicate that the L-arginine–NO pathway is substantially
involved in the cross-talk between the ischemic myocardium
and the coronary microvessels. Kitakaze et al. (21) have
shown that NO plays an important role in regulating
coronary flow during myocardial ischemia.
We have shown in a previous study (15) that the
mechanisms of microvascular dilation in response to GPTX
activation are dependent on the vessel size in vivo—that is,
KATP activation is the main mechanism in small microves-
sels 130 m, whereas both KATP and the NO pathway
contribute to the dilation in larger microvessels (130 m).
Because the DVs in the present study were larger than the
microvessels we used in the previous in vivo study, it is
conceivable that the NO pathway is the main effector of
GPTX activation in large microvessels (250 m). It is
possible that, if we had used smaller DVs, we would have
observed the contribution of KATP in DV dilation.
Myocardial ischemia produced DV constriction in the
presence of L-NNA, whereas PTX only offset the dilation.
These interesting phenomena suggest that the ischemic
myocardium releases vasoconstrictor signals that are PTX-
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sensitive, as well as dilator signals. The mechanisms of the
vasoconstriction require further investigation.
We cannot conclude which upstream mechanisms acti-
vate vascular GPTX during myocardial ischemia. There are
several possible mediators that produce the activation of
GPTX and vasodilation.
Ohno et al. (22) have previously shown that shear stress
activates GPTX in vascular endothelial cells and that this
GPTX activation partly mediates NO production. However,
in the present study, the DV was ligated, and it was a
stop-flow in vitro preparation. Accordingly, it is unlikely
that the activation of GPTX that we observed was caused by
shear stress.
Adenosine, which is produced during myocardial isch-
emia, might activate vascular GPTX. Hein and Kuo (8) have
recently shown that adenosine activates GPTX on the vas-
cular endothelium, leading to the activation of KATP and
NO production, whereas the direct dilator effect of this
nucleoside on vascular smooth muscle is not mediated by
GPTX activation. We did not test the effect of adenosine
blockers in the present study, because the DVs we used were
too large to respond to adenosine (23).
Some studies have addressed the role of adenosine in
microvascular regulation during myocardial ischemia.
Duncker et al. (24) have shown that an adenosine blocker
causes a slight downward shift in the coronary pressure–flow
curve below the autoregulatory breakpoint in exercised,
awake dogs. That study suggested the involvement of
adenosine in vasomotion under the condition of ischemia,
but such an involvement, if any, is not substantial. More-
over, we have previously shown that neither the adenosine
receptor blocker nor adenosine deaminase inhibited the
coronary microvascular dilation at all during reductions in
perfusion pressure (25).
Changes in the pH of the myocardium and interstitium
are among the possible mechanisms. Myocardial ischemia
rapidly produces cardiac interstitial acidosis (26). Extravas-
cular acidosis is known to produce coronary microvascular
dilation through the activation of KATP (27). Ishizaka et al.
(9) have shown that GPTX activation is responsible for
acidosis-induced vasorelaxation. Although G proteins gen-
erally transduce the signal of agonist-bound receptors to
intracellular effectors, recent evidence has shown that
G-protein activation does not necessarily require receptor
occupation (28). Actually, Ishizaka et al. (9) have observed
that purified G proteins reconstituted in liposomes are
directly activated by acidosis.
In the present experiments, the superfusate buffer solu-
tion that was applied to keep the vessels moist and warm
may have attenuated the reduction in pH during ischemia.
However, as the DVs were in direct contact with the
myocardium, protons from the myocardial tissue could
possibly activate the dilator signal transduction in the DVs.
Because acidosis-induced dilation of coronary microvessels
is an important mechanism in metabolic coronary flow
regulation, it is interesting to speculate that protons mediate
the cross-talk between the myocardium and coronary vas-
cular bed.
Conclusions. We have developed a new experimental
model for evaluating the cross-talk between the myocar-
dium and coronary microvessels. The present study has
clearly shown that the ischemic myocardium releases trans-
ferable factors that dilate the coronary microvessels and that
GPTX plays a crucial role in the cross-talk. The L-
arginine–NO pathway is involved in the signal transduction.
The precise upstream and downstream mechanisms remain
to be determined.
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